Path Mental Health vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 36)
Path Mental Health logo

Path Mental Health

EmergingMental Health Tech

Mental Health Marketplace

Mental health provider marketplace matching patients with therapists and psychiatrists accepting insurance; San Francisco-based;

AI VisibilityBeta
Overall Score
D36
Category Rank
#517 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
30
Gemini
35

About

Path Mental Health is a San Francisco-based mental health platform that matches patients with therapists, psychologists, and psychiatrists who accept insurance, addressing the core access barrier in mental healthcare. Path handles the insurance verification, paperwork, and administrative overhead of connecting patients to in-network mental health providers, offering both individual therapy and medication management services. The platform targets the large population of individuals who want to use their health insurance for mental health care but struggle to find providers who are accepting new patients and take their specific insurance plan. Path works with major commercial insurers and provides access to licensed providers via telehealth and in-person sessions depending on location. Founded in 2019, Path raised over $120M from investors including Andreessen Horowitz and Foresite Capital. The company competes with Alma, Headway, and Grow Therapy in the therapist network and patient matching market.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

36
Overall Score
90
#517
Category Rank
#2
80
AI Consensus
83
stable
Trend
up
35
ChatGPT
92
30
Perplexity
93
35
Gemini
89
37
Claude
96
39
Grok
95

Key Details

Category
Mental Health Marketplace
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Path Mental Health
Mental Health Marketplace

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.